PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 162 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2019. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $563,380 | -29.0% | 214,213 | -4.7% | 0.00% | -50.0% |
| Q2 2023 | $793,519 | +47.7% | 224,793 | +29.3% | 0.00% | +100.0% |
| Q1 2023 | $537,091 | -60.5% | 173,816 | -45.9% | 0.00% | -66.7% |
| Q4 2022 | $1,358,917 | +12.6% | 321,257 | -19.1% | 0.00% | +50.0% |
| Q4 2021 | $1,207,000 | +640.5% | 396,967 | +1605.5% | 0.00% | +100.0% |
| Q3 2021 | $163,000 | -69.0% | 23,276 | +71.4% | 0.00% | -50.0% |
| Q1 2019 | $526,000 | +118.3% | 13,576 | +15.1% | 0.00% | 0.0% |
| Q4 2018 | $241,000 | -16.6% | 11,796 | +141.1% | 0.00% | -50.0% |
| Q2 2018 | $289,000 | -44.4% | 4,892 | -72.4% | 0.00% | -20.0% |
| Q1 2016 | $520,000 | -93.0% | 17,700 | -81.4% | 0.01% | -92.9% |
| Q4 2015 | $7,445,000 | +90.9% | 94,965 | +475.1% | 0.07% | +37.3% |
| Q1 2015 | $3,899,000 | +527.9% | 16,513 | +75.4% | 0.05% | +466.7% |
| Q2 2014 | $621,000 | – | 9,416 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,400,000 | $25,032,000 | 1.43% |
| TANG CAPITAL MANAGEMENT LLC | 1,365,376 | $14,241,000 | 1.38% |
| Palo Alto Investors LP | 1,343,897 | $14,017,000 | 0.84% |
| Sofinnova Investments, Inc. | 1,197,630 | $12,491,000 | 0.79% |
| Gyon Technologies Capital Management, LP | 29,745 | $310,000 | 0.75% |
| RICE HALL JAMES & ASSOCIATES, LLC | 455,567 | $4,752,000 | 0.20% |
| GLOBEFLEX CAPITAL L P | 63,226 | $659,000 | 0.17% |
| PDT Partners, LLC | 188,538 | $1,966,000 | 0.13% |
| CADENCE CAPITAL MANAGEMENT LLC | 71,179 | $742,000 | 0.11% |
| FRED ALGER MANAGEMENT, LLC | 2,474,029 | $25,804,000 | 0.08% |